Since the late 1980s, the proto-oncogenic role of RET has been identified and characterized in numerous cancer types, including thyroid, lung, and breast cancer, with RET alterations occurring in less than 5% of all cancer patients [53,54,55]. This evidence concerns the gene RET and breast cancer.